MXPA03006971A - Tratamiento del virus de hepatitis b. - Google Patents
Tratamiento del virus de hepatitis b.Info
- Publication number
- MXPA03006971A MXPA03006971A MXPA03006971A MXPA03006971A MXPA03006971A MX PA03006971 A MXPA03006971 A MX PA03006971A MX PA03006971 A MXPA03006971 A MX PA03006971A MX PA03006971 A MXPA03006971 A MX PA03006971A MX PA03006971 A MXPA03006971 A MX PA03006971A
- Authority
- MX
- Mexico
- Prior art keywords
- hepatitis
- virus treatment
- compositions
- hbv
- hbv antigen
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 abstract 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invencion se refiere a composiciones que contienen antigeno de HBV que son utiles paya tratar o prevenir infeccion por HBV. El contenido de las composiciones puede variar, como se describe en la presente, pero las composiciones comprenden una proteina de tension, o una porcion (por ejemplo, un fragmento) o derivado de la misma, y un antigeno de HBV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26673301P | 2001-02-05 | 2001-02-05 | |
PCT/US2002/003460 WO2002062959A2 (en) | 2001-02-05 | 2002-02-05 | Hepatitis b virus treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03006971A true MXPA03006971A (es) | 2004-05-05 |
Family
ID=23015782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03006971A MXPA03006971A (es) | 2001-02-05 | 2002-02-05 | Tratamiento del virus de hepatitis b. |
Country Status (16)
Country | Link |
---|---|
US (2) | US6921534B2 (es) |
EP (1) | EP1357940A4 (es) |
JP (1) | JP2005505238A (es) |
KR (1) | KR20030074787A (es) |
CN (1) | CN1264572C (es) |
AU (1) | AU2002247084B2 (es) |
BR (1) | BR0206995A (es) |
CA (1) | CA2437503A1 (es) |
HK (1) | HK1062579A1 (es) |
IL (2) | IL157251A0 (es) |
MX (1) | MXPA03006971A (es) |
NZ (1) | NZ527664A (es) |
PL (1) | PL373675A1 (es) |
RU (1) | RU2295536C2 (es) |
WO (1) | WO2002062959A2 (es) |
ZA (1) | ZA200306040B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1107681C (zh) * | 2000-08-11 | 2003-05-07 | 中国科学院微生物研究所 | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 |
CN100381463C (zh) * | 2002-09-18 | 2008-04-16 | 中国人民解放军免疫学研究所 | 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途 |
GB0303507D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
CN1727362B (zh) * | 2004-07-30 | 2010-12-01 | 中国人民解放军第二军医大学 | 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用 |
JP4736413B2 (ja) * | 2004-12-14 | 2011-07-27 | 富士ゼロックス株式会社 | 生体分子保持物及び生体分子の保存方法 |
EP1835933A4 (en) * | 2005-01-04 | 2015-01-07 | Yeda Res & Dev | HSP60, PEPTIDES HSP60 AND T-CELL VACCINES FOR IMMUNOMODULATION |
US20080279878A1 (en) | 2005-03-14 | 2008-11-13 | B.G. Negev Technologies And Applications Ltd. | Compositions of Hsp60 Peptides and Viral Antigens for Vaccination and Diagnosis |
US7622121B2 (en) * | 2005-09-21 | 2009-11-24 | New York University | Heat shock proteins from Mycobacterium leprae and uses thereof |
CN101307310B (zh) * | 2007-05-15 | 2012-08-08 | 康泰生医科技股份有限公司 | 具有提高产率及免疫原性的重组蛋白质表达系统 |
US8088392B2 (en) * | 2007-06-18 | 2012-01-03 | Yunxu Cao | Capsid proteins and uses therefore |
WO2008154867A1 (en) * | 2007-06-18 | 2008-12-24 | Shanghai Zerun-Ankegens Biopharmaceutical Co., Ltd | Material with immunogenicity |
KR101281098B1 (ko) * | 2011-06-30 | 2013-07-02 | 주식회사 녹십자 | B형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도 |
TWI575070B (zh) * | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
WO2019123252A1 (en) * | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Hepatitis b virus (hbv) vaccines and uses thereof |
AU2020297008A1 (en) * | 2019-06-18 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis B virus (HBV) vaccines and HBV-targeting RNAi |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666847A (en) * | 1981-01-16 | 1987-05-19 | Collaborative Research, Inc. | Recombinant DNA means and method |
US4797359A (en) * | 1983-05-10 | 1989-01-10 | Board Of Regents, The University Of Texas System | Heat shock regulated production of selected and fused proteins in yeast |
US4547368A (en) * | 1983-12-20 | 1985-10-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Hepatitis B core antigen vaccine made by recombinant DNA |
GB8404280D0 (en) | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
IL71683A0 (en) | 1984-04-27 | 1984-09-30 | Yeda Res & Dev | Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria |
US4918164A (en) * | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
US4784941A (en) * | 1985-04-08 | 1988-11-15 | Genetic Systems Corporation | Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV |
US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
US4906742A (en) | 1986-07-31 | 1990-03-06 | Whitehead Institute For Biomedical Research | Encoding antigens of M. Leprae |
NL8701163A (nl) | 1986-09-09 | 1988-04-05 | Nederlanden Staat | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
WO1988005823A2 (en) | 1987-02-02 | 1988-08-11 | Whitehead Institute For Biomedical Research | Mycobacterium tuberculosis genes encoding protein antigens |
US4952395A (en) | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
US4918166A (en) | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
US5256767A (en) * | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
NL8703107A (nl) | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
US5204259A (en) * | 1988-05-06 | 1993-04-20 | Pharmacia Genetic Engineering, Inc. | Methods and systems for producing HIV antigens |
EP0419569B1 (en) | 1988-06-15 | 1995-09-06 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US5114844A (en) | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
DE69034100T2 (de) | 1989-06-19 | 2004-06-09 | Whitehead Institute For Biomedical Research, Cambridge | Verktorvermittelte genominsertion und expression von dna in bcg |
GB8919321D0 (en) | 1989-08-25 | 1989-10-11 | Univ London | Treatment of chronic inflammatory conditions |
GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
US5348945A (en) | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
DK0556248T3 (da) | 1990-11-08 | 1997-10-27 | Univ London | Mycobacterium som adjuvans til antigener |
GB9024320D0 (en) | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
GB2251186A (en) | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
EP0491077A1 (en) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
US6297048B1 (en) * | 1992-02-04 | 2001-10-02 | Chiron Corporation | Hepatitis therapeutics |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
US5580563A (en) | 1992-05-01 | 1996-12-03 | Tam; James P. | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof |
GB9211736D0 (en) | 1992-06-03 | 1992-07-15 | Univ Cardiff | Allergic treatment |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5736146A (en) | 1992-07-30 | 1998-04-07 | Yeda Research And Development Co. Ltd. | Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them |
DK0700445T3 (da) | 1993-06-04 | 2002-05-13 | Whitehead Biomedical Inst | Stressproteiner og anvendelser deraf |
WO1995004548A1 (en) * | 1993-08-11 | 1995-02-16 | Jenner Technologies | Prostatic cancer vaccine |
US5750119A (en) | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
IL109790A0 (en) | 1994-05-25 | 1994-08-26 | Yeda Res & Dev | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
AU724399B2 (en) | 1995-08-18 | 2000-09-21 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5985270A (en) | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
WO1997026910A2 (de) | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
ES2258796T3 (es) | 1996-11-26 | 2006-09-01 | Stressgen Biotechnologies Corporation | Proteinas de fusion que contienen proteinas de estres para inducir respuestas inmunitarias. |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
US5830464A (en) | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
WO1998035705A1 (en) | 1997-02-18 | 1998-08-20 | Whitehead Institute For Biomedical Research | Use of heat shock proteins to deliver moieties into cells |
ES2266652T3 (es) | 1997-08-05 | 2007-03-01 | Stressgen Biotechnologies Corporation | Respuestas inmunologicas contra los antigenos de hpv provocadas por compuestos que contienen un antigeno de hpv y una proteina de stress o un vector de expresion capaz de expresar dichas proteinas. |
US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
NZ506245A (en) * | 1998-02-12 | 2003-08-29 | Immune Complex Corp | Strategically modified hepatitis b core proteins and their derivatives |
US6451316B1 (en) | 1998-10-05 | 2002-09-17 | University Of Conneticut Health Center | Methods for generating antigen-reactive T cells in vitro |
US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
AU1055599A (en) * | 1998-11-17 | 2000-06-05 | Joo-Sul Kim | Programmable time switch |
CA2378097A1 (en) | 1999-07-08 | 2001-01-18 | Stressgen Biotechnologies Corporation | Induction of a th1-like response in vitro |
WO2001017554A1 (en) | 1999-09-10 | 2001-03-15 | Fordham University | Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins |
US20010034042A1 (en) | 2000-01-20 | 2001-10-25 | Srivastava Pramod K. | Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents |
AU2001229597A1 (en) | 2000-01-21 | 2001-07-31 | University Of Connecticut Health Center | Compositions and methods to treat neurodegenerative disorders |
WO2001053457A2 (en) | 2000-01-21 | 2001-07-26 | University Of Connecticut Health Center | Vaccines against neurodegenerative disorders |
WO2001052890A1 (en) | 2000-01-21 | 2001-07-26 | University Of Connecticut Health Center | Heat shock/stress protein complexes as vaccines against neurodegenerative disorders |
EE200200709A (et) | 2000-06-26 | 2004-08-16 | Stressgen Biotechnologies Corporation | Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine |
CN1107681C (zh) | 2000-08-11 | 2003-05-07 | 中国科学院微生物研究所 | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 |
-
2002
- 2002-02-05 JP JP2002563296A patent/JP2005505238A/ja active Pending
- 2002-02-05 CA CA002437503A patent/CA2437503A1/en not_active Abandoned
- 2002-02-05 MX MXPA03006971A patent/MXPA03006971A/es active IP Right Grant
- 2002-02-05 EP EP02714842A patent/EP1357940A4/en not_active Ceased
- 2002-02-05 IL IL15725102A patent/IL157251A0/xx unknown
- 2002-02-05 CN CNB028045769A patent/CN1264572C/zh not_active Expired - Fee Related
- 2002-02-05 US US10/068,059 patent/US6921534B2/en not_active Expired - Fee Related
- 2002-02-05 KR KR10-2003-7010313A patent/KR20030074787A/ko not_active Application Discontinuation
- 2002-02-05 WO PCT/US2002/003460 patent/WO2002062959A2/en active Application Filing
- 2002-02-05 NZ NZ527664A patent/NZ527664A/en unknown
- 2002-02-05 AU AU2002247084A patent/AU2002247084B2/en not_active Ceased
- 2002-02-05 BR BR0206995-4A patent/BR0206995A/pt not_active IP Right Cessation
- 2002-02-05 RU RU2003127021/13A patent/RU2295536C2/ru not_active IP Right Cessation
- 2002-02-05 PL PL02373675A patent/PL373675A1/xx unknown
-
2003
- 2003-08-05 IL IL157251A patent/IL157251A/en not_active IP Right Cessation
- 2003-08-05 ZA ZA200306040A patent/ZA200306040B/xx unknown
-
2004
- 2004-07-22 HK HK04105433A patent/HK1062579A1/xx not_active IP Right Cessation
- 2004-09-14 US US10/941,049 patent/US20050152917A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6921534B2 (en) | 2005-07-26 |
NZ527664A (en) | 2006-12-22 |
JP2005505238A (ja) | 2005-02-24 |
AU2002247084B2 (en) | 2007-01-04 |
EP1357940A4 (en) | 2004-03-17 |
ZA200306040B (en) | 2004-11-17 |
BR0206995A (pt) | 2005-08-16 |
WO2002062959A2 (en) | 2002-08-15 |
RU2295536C2 (ru) | 2007-03-20 |
US20020155434A1 (en) | 2002-10-24 |
CA2437503A1 (en) | 2002-08-15 |
HK1062579A1 (en) | 2004-11-12 |
CN1491116A (zh) | 2004-04-21 |
WO2002062959A3 (en) | 2003-03-06 |
CN1264572C (zh) | 2006-07-19 |
IL157251A (en) | 2009-05-04 |
KR20030074787A (ko) | 2003-09-19 |
IL157251A0 (en) | 2004-02-19 |
RU2003127021A (ru) | 2005-01-20 |
PL373675A1 (en) | 2005-09-05 |
US20050152917A1 (en) | 2005-07-14 |
EP1357940A2 (en) | 2003-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03006971A (es) | Tratamiento del virus de hepatitis b. | |
MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
EA200201279A1 (ru) | Способы и композиции для лечения вирусного гепатита c | |
DK1090033T3 (da) | Partikler af HCV-kappeproteiner: Anvendelse til vaccination | |
ATE326236T1 (de) | Hpv-e7 zur behandlung von menschlichem papillomavirus | |
AU2002360592A8 (en) | Inhibitors of hepatitis c virus | |
EA200700243A1 (ru) | Способы лечения гепатита с | |
ATE327246T1 (de) | Hepatitis c tripeptid inhibitoren | |
DK1255815T3 (da) | Porcint reproduktivt og respiratorisk syndromvirus til fremgangsmåder til anvendelse | |
EP1256348A4 (en) | REMEDIES AGAINST HEPATITIS | |
WO2002013855A3 (en) | Vaccines containing ribavirin and methods of use thereof | |
EP1399163A4 (en) | COMPOUNDS, METHODS AND COMPOSITIONS FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA (VBVD) INFECTION AND HEPATITIS C (HCV) VIRUS INFECTION | |
AU2002346686A1 (en) | Compositions and method for treating hepatitis virus infection | |
DE602006014720D1 (de) | Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c | |
WO2007121491A8 (en) | Hcv vaccinations | |
WO2004043404A3 (en) | Process for designing inhibitors of influenza virus non-structural protein 1 | |
ATE425187T1 (de) | Materialien und methoden zur behandlung von hepatitis c | |
GB9723945D0 (en) | Tissue cement | |
DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
WO2005056051A3 (en) | Hepatitis b vaccines and compositions | |
WO2001046696A3 (en) | Methods and compositions for detecting hepatitis e virus | |
ATE409705T1 (de) | Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs | |
TR200202169T1 (tr) | Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri. | |
ATE476197T1 (de) | Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon | |
WO2004064784A3 (en) | Composition and method for preventing or treating a virus infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights | ||
HC | Change of company name or juridical status |